Skip to main content
Clinical Trials/NCT02635321
NCT02635321CompletedNot Applicable

MRI and Muscle Involvement in Patients With Mutations in GMPPB

Rigshospitalet, Denmark1 site in 1 country4 target enrollmentStarted: November 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
4
Locations
1
Primary Endpoint
MRI scan for qualitative analysis of muscle involvement

Study Overview

Brief Summary

Limb girdle muscular dystrophies (LGMD) are a very heterogeneous group of muscle disorders characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. LGMD is classified based on its inheritance pattern and genetic cause into more than 31 different types.

A new type - type 2T has been found. The genetic cause of type 2T is mutations in Guanosine Diphosphate (GDP)-mannose pyrophosphorylase B (GMPPB). Mutations in GMPPB can also cause Congenital muscular dystrophies (CMD). Only 41 patients with mutations in GMPPB has been reported.

In this study, the investigators examine five new cases with the LGMD phenotype. The primary aim is to examine the muscle involvement using MRI.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Persons with genetically verified mutations in GMPPB

Exclusion Criteria

  • All contraindications for undergoing an MRI scan

Outcomes

Primary Outcomes

MRI scan for qualitative analysis of muscle involvement

Time Frame: One MRI scan per subject (exam lasts approximately 60 min.)

The MRI protocol include T1-weighted brain and whole body examination. Four cross-sectional slices at shoulder, lumbar back, thigh and calf are chosen for qualitative analysis using the grading scale developed by Mercuri et al. (2007).

Secondary Outcomes

  • Muscle biopsy for biochemical investigation(One muscle biopsy per subject (last approximately 15 min.))
  • 10 meter walk test(Exam last approximately 5 min.)
  • Neurological examination and test of muscle strength(Exam last approximately 15 min.)
  • Questionnaires(Data will be collected once for patients with LGMD 2T (exam last approximately 45 min.))
  • Heart examination(Exam last approximately 45 min)
  • Forced Vital Capacity (FVC)(Exam last approximately 15 min)
  • Electromyography (EMG)(Exam last approximately 30 min)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sofie Thurø Østergaard

Bachelor of Science

Rigshospitalet, Denmark

Study Sites (1)

Loading locations...

Similar Trials